The research team developed two FTO inhibitors, FB23 and FB23-2, and used CRISPR-Cas9 gene editing to create stable FTO knockout (KO) AML cell lines to assess the efficacy of these inhibitors. The gene discussed is FTO; the disease is acute myeloid leukemia.